Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The Coronavirus Disease 2019 (COVID-19) pandemic has claimed over 5 million lives globally. Fortunately, a substantial and growing number of SARS-CoV-2 vaccines with very high efficacy have been developed, manufactured, and rapidly approved. Novel mRNA vaccines such as the BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) have reported a stunning >94% efficacy against COVID-19. However, global access has not been equitable, with many low- and middle-income countries having no vaccine access or access under emergency use mainly to traditional inactivated SARS-CoV2-2 vaccines such as BBIBP-CorV (Sinopharm Beijing), CoronaVac (Sinovac) and BBV152 (Bharat Biotech). Emerging studies have shown that lower concentrations of neutralizing antibodies (Nab) are attained after CoronaVac than after an mRNA-based vaccine in healthy individuals. This difference seems to be more pronounced in immunocompromised patients who are at higher risk of severe COVID-19 and death from COVID-19. As such, several countries including the United States, Israel and Chile have recommended a third vaccine dose for high-risk populations. However, it is not currently known which is the best vaccine combination regarding immunogenicity, particularly in these vulnerable patients.
This observational study will explore the humoral and cellular response to a SARS-CoV-2 BNT162b2 vaccine booster in solid organ transplant patients who received two previous doses of the inactivated Coronavac or two doses of BNT162b2 vaccines.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Three doses of BNT162b2 vaccine | Solid organ transplant patients who received three doses of BNT162b2 |
| |
| Two doses of Coronavac and one of BNT162b2 vaccine | Solid organ transplant patients who received two doses of CoronaVac and one dose of BNT162b2 |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Three doses of SARS-CoV-2 BNT162b2 vaccine (observational) | Biological | Two doses of SARS-CoV-2 BNT162b2 mRNA vaccine, followed by a booster (3rd) dose of SARS-CoV-2 BNT162b2 mRNA vaccine. |
| Measure | Description | Time Frame |
|---|---|---|
| IgG seropositivity 8-12 weeks after third dose BNT162b2 (booster) vaccine. | 8-12 weeks after booster vaccine |
| Measure | Description | Time Frame |
|---|---|---|
| Proportion of positive neutralizing antibodies 8 to 12 weeks after third dose BNT162b2 (booster) vaccine. | 8-12 weeks after booster vaccine | |
| Neutralizing geometric mean titers 8 to 12 weeks after third dose of BNT162b2 (booster) vaccine. | 8-12 weeks after booster vaccine |
| Measure | Description | Time Frame |
|---|---|---|
| The number of IFN-y-spot forming T cells SARS-CoV-2 specific after third dose of BNT162b2 (booster) vaccine. | 8-12 weeks after booster vaccine |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Solid organ transplant patients in the last 10 years and currently under immunosuppressive therapy
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Pontificia Universidad Católica de Chile | Santiago | Chile |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 36185969 | Derived | Dib M, Le Corre N, Ortiz C, Garcia D, Ferres M, Martinez-Valdebenito C, Ruiz-Tagle C, Ojeda MJ, Espinoza MA, Jara A, Arab JP, Rabagliati R, Vizcaya C, Ceballos ME, Sarmiento M, Mondaca S, Vinuela M, Pastore A, Szwarcfiter V, Galdames E, Barrera A, Castro P, Galvez NM, Soto JA, Bueno SM, Kalergis AM, Nervi B, Balcells ME. SARS-CoV-2 vaccine booster in solid organ transplant recipients previously immunised with inactivated versus mRNA vaccines: A prospective cohort study. Lancet Reg Health Am. 2022 Dec;16:100371. doi: 10.1016/j.lana.2022.100371. Epub 2022 Sep 23. |
Not provided
Not provided
Anonymized IPD may be shared under institutional request if IRB requirements are met.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Two doses of CoronaVac and one dose of BNT162b2 SARS-CoV-2 vaccine (observational) | Biological | Two doses of CoronaVac SARS-CoV-2 inactivated vaccine, followed by a booster (3rd) dose of BNT162b2 mRNA vaccine. |
|
| ID | Term |
|---|---|
| D000086382 | COVID-19 |
| ID | Term |
|---|---|
| D011024 | Pneumonia, Viral |
| D011014 | Pneumonia |
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
| D014777 | Virus Diseases |
| D018352 | Coronavirus Infections |
| D003333 | Coronaviridae Infections |
| D030341 | Nidovirales Infections |
| D012327 | RNA Virus Infections |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C000722216 | sinovac COVID-19 vaccine |
Not provided
Not provided
Not provided